Latest News
Exosome Diagnostics Presents Data Demonstrating Utility of Urine Exosome Technology to Predict Prostate Biopsy Outcome at American Urological Association Annual Meeting
NEW YORK May 8, 2013 — Exosome Diagnostics, a leading developer of biofluid-based molecular diagnostic products for use in personalized medicine research and clinical diagnostics, today announced the presentation of data at the American Urological Association Annual Meeting in San Diego demonstrating the performance of urine exosome technology in accurately predicting the outcome of a prostate biopsy… More…
Exosome Diagnostics Presents Data Demonstrating Clinical Applications of Exosome Technology in Brain Cancer, Prostate Cancer, and Alzheimer's Disease at the International Society for Extracellular Vesicles 2013 Annual Meeting
NEW YORK April 16, 2013 — Exosome Diagnostics, a developer of biofluid-based molecular diagnostic products for use in personalized medicine, today announced data demonstrating exosome technology performance in clinical applications which will be presented at the International Society for Extracellular Vesicles 2013 (ISEV 2013) annual meeting, April 16–20, in Boston. The ISEV meeting is… More…
Exosome Presents Late-Breaking Study Demonstrating Ability to Profile RNA from Archived Clinical Trial Blood Samples at 2013 American Association of Cancer Research Annual Meeting
NEW YORK April 8, 2013 — Exosome Diagnostics, a leading developer of biofluid-based molecular diagnostics for use in personalized medicine, today announced that the company is presenting a late-breaking abstract at the AACR Annual Meeting 2013, in Washington D.C. The abstract is titled "Exosome profiling of mRNAs and miRNAs in serum samples from GBM (glioblastoma multiforme) patients." More…
Exosome Diagnostics Selects Promega Corp. for cGMP Clinical Sample Concentrator Kit
NEW YORK October 26, 2012 — Exosome Diagnostics today announced it has reached an agreement with Promega Corporation to be the exclusive supplier of its Urine Clinical Sample Concentrator Kit. Promega will manufacture the Clinical Sample Concentrator Kit under current good manufacturing practices (cGMP) in their Madison, Wisconsin manufacturing facility. The kit incorporates Exosome's proprietary method for concentration of urinary exosomes… More…
Exosome Diagnostics Signs Agreement with Life Technologies to Use Real-Time PCR Platform for Exosome Biofluid In Vitro Oncology Diagnostics
NEW YORK June 4, 2012 — Exosome Diagnostics today announced it has reached agreement with Life Technologies to use the Applied Biosystems® (ABI) 7500 Fast Dx Real-Time PCR Instrument for the Company’s exosome biofluid in-vitro diagnostics oncology program. Exosome Diagnostics plans to validate the ABI instrument platform with exosome biofluid RNA isolation technology kits in upcoming multi-center clinical trials in brain cancer and prostate cancer beginning in 2012. More…
Exosome Diagnostics Presents Data at American Urology Association Demonstrating Potential Utility of Urine Exosomes to Non-invasively Detect and Manage Prostate Cancer
NEW YORK May 23, 2012 — Exosome Diagnostics today presented two clinical studies demonstrating the potential utility of non-invasive sampling of patients' urine to detect and manage prostate cancer. More…
Kapil Dhingra, Former Head of Roche Oncology, Joins Exosome Diagnostics Board of Directors
NEW YORK March 28, 2012 - Exosome Diagnostics today announced that Kapil Dhingra, MB, BS, has joined the Exosome Diagnostics Board of Directors. More…
Accelerate Brain Cancer Cure and Exosome Diagnostics Collaborate to Advance Clinical Studies of Exosome Biofluid Molecular Diagnostics Technology in Brain Cancer
WASHINGTON, DC and NEW YORK February 6, 2012 - Accelerate Brain Cancer Cure (ABC2) and Exosome Diagnostics are collaborating with leading academic medical centers to accelerate clinical validation of Exosome's blood and cerebrospinal fluid-based molecular diagnostics technology in brain cancer. The collaboration will explore the capabilities of Exosome RNA biofluid-based diagnostic technology for early identification, progression monitoring and disease risk stratification in glioma, the most common form of brain cancer. More…
EUR 1.0 Million Grant Awarded to Exosome Diagnostics and Ludwig Maximilian University from German Federal Ministry for Education and Research to Develop Biofluid-Derived Exosome Diagnostics
MUNICH February 1, 2012 - Exosome Diagnostics GmbH, a subsidiary of Exosome Diagnostics, Inc., and the Department of Dermatology at the Ludwig Maximilian University (LMU) announce the awarding of a EUR one million grant from the German Federal Ministry for Education and Research (BMBF) to develop blood-based diagnostic tests from the stable RNA content accessible in plasma-derived exosomes. The grant will help fund development of exosome-based diagnostics technology to detect tumor specific mutations in the blood from patients with malignant cancer in order to enable monitoring of disease recurrence, aid therapy selection and possibly improve early tumor detection. The grant was awarded under the Munich Leading-Edge Cluster Program "m4 — Personalized Medicine and Targeted Therapies". More…
The Prostate Cancer Foundation and Exosome Diagnostics Collaborate to Accelerate Clinical Validation of Exosome Biofluid Molecular Diagnostics in Prostate Cancer
SANTA MONICA, CA and NEW YORK, NY (USA) October 13, 2011 - The Prostate Cancer Foundation (PCF) and Exosome Diagnostics today are announcing a multi-year collaboration to accelerate clinical validation of Exosome's biofluid molecular diagnostics technology in prostate cancer. In addition, Howard Soule, PhD, chief science officer of PCF, will join the Exosome Diagnostics Scientific Advisory Board. More…
Exosome Diagnostics Announces Additions to Management and Scientific Advisory Board as Company Expands Clinical Validation Studies in Oncology
NEW YORK (NY, USA) October 3, 2011 - Exosome Diagnostics, Inc. today announced the appointment of' David Okrongly, PhD, as chief operating officer, Michael Donovan, MD, PhD, as chief medical officer, and Sally Bowden as director of regulatory affairs. The company also welcomed new members to its Scientific Advisory Board. More…
Exosome Diagnostics Announces Expansion of Scientific Advisory Board
NEW YORK (NY, USA) May 24, 2011 — Exosome Diagnostics, Inc. today announced the appointments of Bob Carter MD, PhD, Carlos Cordon-Cardo MD, PhD, Keith Flaherty MD, John Quackenbush, PhD; to its Scientific Advisory Board (SAB). More…
Key Genes Associated with Cancer Found in Circulating Blood Microvesicles
NEW YORK (NY, USA), MUNICH (GERMANY) February 3, 2011 — Exosome Diagnostics, Inc. today announced a study published in Nature Communications by researchers at Massachusetts General Hospital/Harvard Medical School show that tumor microvesicles contain retro-transposons, also known as "jumping genes" as well as amplified oncogene sequences. These discoveries expand further on the use of microvesicles such as exosomes as a powerful blood-based cancer diagnostic medium. More…